{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:05:45Z","timestamp":1791655545169,"version":"4.3.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","respiratoryinvestigation.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.resinv.2017.11.009","type":"journal-article","created":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T23:52:12Z","timestamp":1513900332000},"page":"179-183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical impact of minocycline on afatinib-related rash in patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations"],"prefix":"10.1016","volume":"56","author":[{"given":"Ayano","family":"Goto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Koda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Akahori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Koyauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Amano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Kakutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshi","family":"Yokomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2017.11.009_bib1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","article-title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial","volume":"17","author":"Park","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.resinv.2017.11.009_bib2","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1200\/JCO.2015.63.4154","article-title":"Randomized Phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L","volume":"34","author":"Urata","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2017.11.009_bib3","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/cas.12723","article-title":"Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activatingEGFRmutations: Subgroup analysis of LUX-Lung 3","volume":"106","author":"Kato","year":"2015","journal-title":"Cancer Sci"},{"key":"10.1016\/j.resinv.2017.11.009_bib4","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.resinv.2017.11.009_bib5","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2017.11.009_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/734249","article-title":"Epidermal growth factor receptor inhibitors: a review of cutaneous adverse events and management","volume":"2014","author":"Chanprapaph","year":"2014","journal-title":"Dermat Res Pract"},{"key":"10.1016\/j.resinv.2017.11.009_bib7","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jaad.2013.02.025","article-title":"Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer","volume":"69","author":"Kiyohara","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.resinv.2017.11.009_bib8","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00520-011-1197-6","article-title":"Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities","volume":"19","author":"Lacouture","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.resinv.2017.11.009_bib9","first-page":"195","article-title":"Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician","volume":"9","author":"Gutzmer","year":"2011","journal-title":"JDDG: J Dtsch Dermatol Ges"},{"key":"10.1016\/j.resinv.2017.11.009_bib10","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/annonc\/mdq387","article-title":"Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion","volume":"22","author":"Potthoff","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.resinv.2017.11.009_bib11","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaad.2005.10.004","article-title":"Tetracyclines: nonantibiotic properties and their clinical implications","volume":"54","author":"Sapadin","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.resinv.2017.11.009_bib12","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","article-title":"Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors","volume":"16","author":"Segaert","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.resinv.2017.11.009_bib13","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1200\/JCO.2015.62.3918","article-title":"Pan Canadian Rash Trial: a randomized phase III trial evaluating the impact of a prophylactic skin treatment regimen on epidermal growth factor receptor-tyrosine kinase inhibitor-induced skin toxicities in patients with metastatic lung cancer","volume":"34","author":"Melosky","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2017.11.009_bib14","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","article-title":"Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer","volume":"28","author":"Lacouture","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2017.11.009_bib15","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.lungcan.2015.03.019","article-title":"Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients","volume":"88","author":"Arrieta","year":"2015","journal-title":"Lung Cancer"},{"issue":"Pt 2","key":"10.1016\/j.resinv.2017.11.009_bib16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1242\/jcs.110.2.113","article-title":"EGF-R dependent regulation of keratinocyte survival","volume":"110","author":"Rodeck","year":"1997","journal-title":"J Cell Sci"},{"key":"10.1016\/j.resinv.2017.11.009_bib17","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0002-9440(10)63654-1","article-title":"Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation","volume":"163","author":"Mascia","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.resinv.2017.11.009_bib18","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1158\/1535-7163.MCT-04-0238","article-title":"Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment","volume":"4","author":"Woodworth","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.resinv.2017.11.009_bib19","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/infdis\/129.2.110","article-title":"Effects of tetracycline on leukotaxis","volume":"129","author":"Martin","year":"1974","journal-title":"J Infect Dis"},{"key":"10.1016\/j.resinv.2017.11.009_bib20","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/1523-1747.ep12610281","article-title":"Anti-inflammatory effects of antimicrobial agents: an in vivo study","volume":"65","author":"Plewig","year":"1975","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.resinv.2017.11.009_bib21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/1523-1747.ep12543487","article-title":"The effect of antimicrobial agents on leukocyte chemotaxis","volume":"70","author":"Esterly","year":"1978","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.resinv.2017.11.009_bib22","first-page":"443","article-title":"Inhibition of mitogen-induced human lymphocyte proliferative responses by tetracycline analogues","volume":"35","author":"Thong","year":"1979","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.resinv.2017.11.009_bib23","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/art.1780370505","article-title":"Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial","volume":"37","author":"Kloppenburg","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.resinv.2017.11.009_bib24","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/brain\/awf133","article-title":"Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis","volume":"125","author":"Brundula","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.resinv.2017.11.009_bib25","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.jaad.2016.01.019","article-title":"Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: a randomized, open-label trial","volume":"74","author":"Deplanque","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.resinv.2017.11.009_bib26","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2007.12.6987","article-title":"Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption","volume":"25","author":"Scope","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534517301545?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534517301545?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:56:09Z","timestamp":1660179369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534517301545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S2212534517301545"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2017.11.009","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical impact of minocycline on afatinib-related rash in patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2017.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}